新开河品牌怎么样 申请店铺

我要投票 新开河在人参行业中的票数:158 更新时间:2025-03-26
新开河是哪个国家的品牌?「新开河」是 康美药业股份有限公司 旗下著名品牌。该品牌发源于吉林省通化市,由创始人马董在1997年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力新开河品牌出海!通过在本页面挂载新开河品牌的产品链接和联系邮箱,可以提高新开河产品曝光!跨境电商爆单神器,目前只要100元/年哦~

新开河怎么样

成立于1997年,较早布局中医药全产业,以中药饮片为核心,以智慧药房为抓手,打造大健康+大平台+大数据+大服务体系


康美药业股份有限公司(600518)成立于1997年,于2001年在上交所上市。公司秉承“心怀苍生、大爱无疆”的核心价值观和“用爱感动世界、用心经营健康”的经营理念,在国家振兴中医药事业战略指引下,较早布局中医药全产业,以中药饮片为核心,以智慧药房为抓手,打造“大健康+大平台+大数据+大服务”体系,成为中医药全产业链服务型“智慧+”大健康产业上市企业。

康美药业上至药材种植、药材交易,下至生产开发、终端销售,已基本贯穿中医药产业链的上、中、下游产业,业务渗透中医药全产业链的各个关键环节,有效地整合全产业链资源。公司先后在全国各地投资建立140多家涵盖药材种植、中药材交易市场、现代物流中心和产业基地等业务的企业。

在全国建立了17个中药饮片和医药现代化生产基地,与超过2000家医疗机构、20万家药店建立了合作关系,年门诊总量达到2.5亿人次以上,投资管理康美医院、康美梅河口中心医院、康美通辽医院、康美开原市中心医院、康美通城人民医院、康美柳河中心医院等多家公立医院,在100多家公立医院开展医药物流延伸配送服务。

公司以国家中医药管理局信息化医疗服务平台试点单位为契机,把互联网深度布局全产业链中,以中药饮片为核心,以智慧药房为抓手,围绕“大健康+大平台+大数据+大服务”体系,以全产业链资源优势,积极探索中医药工业智能制造4.0,较早打造“智慧药房”模式。“智慧药房”模式上升为行业标准,为患者提供了“一站式”药事服务。截止2018年三季度,康美智慧药房累计处方量710万张,服务患者250万人,实现了“让信息多跑路,让群众少跑腿”。

康美药业丰富的医疗资源为公司以互联网思维、技术,改造和升级传统医疗健康产业,打造具有优良用户体验、覆盖全生命周期、一站式完整医疗服务闭环的移动健康管理大平台,奠定了坚实的基础。


Founded in 1997, Kangmei Pharmaceutical Co., Ltd. (600518) was founded in 1997 and listed on the Shanghai Stock Exchange in 2001. It has an early layout of the whole industry of traditional Chinese medicine, with herbal pieces as the core and smart pharmacies as the starting point to build a big health + big platform + big data + big service system. The company adheres to the core values of "caring for the world, loving the boundless" and the business philosophy of "moving the world with love and managing health with heart". Under the guidance of the national strategy of rejuvenating the cause of traditional Chinese medicine, the whole industry of traditional Chinese medicine is laid out earlier, with Chinese herbal pieces as the core and smart pharmacies as the starting point, and the system of "big health + big platform + big data + big service" is built to become the whole industry of traditional Chinese medicine Chain service-oriented "wisdom +" large health industry listed enterprises. Kangmei pharmaceutical industry has basically run through the upstream, midstream and downstream industries of TCM industry chain from the planting and trading of medicinal materials to the production and development and terminal sales. Its business penetrates all key links of the whole industry chain of TCM and effectively integrates the resources of the whole industry chain. The company has successively invested and established more than 140 enterprises covering medicine planting, Chinese medicine trading market, modern logistics center and industrial base. It has established 17 modern production bases of Chinese herbal pieces and medicine, established cooperative relations with more than 2000 medical institutions and 200000 pharmacies, with an annual outpatient volume of more than 250 million person times, invested and managed many hospitals, including Kangmei hospital, Kangmei Meihekou Central Hospital, Kangmei Tongliao hospital, Kangmei Kaiyuan Central Hospital, Kangmei Tongcheng people's Hospital and Kangmei Liuhe central hospital Public hospitals, in more than 100 public hospitals to carry out pharmaceutical logistics extended distribution services. Taking the opportunity of the pilot unit of the informatization medical service platform of the State Administration of traditional Chinese medicine, the company takes the Internet as an in-depth layout in the whole industry chain, with Chinese herbal pieces as the core, smart pharmacy as the starting point, around the "big health + big platform + big data + big service" system, and with the resource advantages of the whole industry chain, actively explores the intelligent manufacturing 4.0 of the traditional Chinese medicine industry, and builds the "smart pharmacy" model earlier Type. The mode of "smart pharmacy" has risen to the industry standard, providing patients with "one-stop" pharmaceutical services. As of the third quarter of 2018, Kangmei smart pharmacy has accumulated 7.1 million prescriptions, served 2.5 million patients, and realized "let more information run more, let the masses run less". Kangmei pharmaceutical's rich medical resources have laid a solid foundation for the company to transform and upgrade the traditional medical and health industry with internet thinking and technology, and to build a mobile health management platform with excellent user experience, covering the whole life cycle and one-stop complete medical service closed-loop.

本文链接: https://brand.waitui.com/f1e75a350.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

云迹科技与奇安信达成战略合作

36氪获悉,云迹科技宣布与网络安全领域的领军者奇安信集团达成战略合作。双方将围绕打造安全的机器人服务智能体开展产品和技术的深度合作,旨在通过技术创新与行业安全标准共建,加强机器人服务智能体的全面安全防护升级,推进“机器人安全身份证”的落地,推动中国服务智能体行业的健康发展。

2小时前

中国银行:2024年税后利润2527.19亿元

36氪获悉,中国银行发布公告,2024年全年营收6327.71亿元,税后利润2527.19亿元。董事会建议派发2024年度末期普通股股利每10股人民币1.216元(税前)。

2小时前

戴尔2025财年员工人数减少10%

戴尔当地时间3月25日在年报中表示,截至2025年1月31日,公司拥有约108000名员工,低于去年同期的约12万人。2025财年,公司始终致力于严格的成本管理,采取某些措施来降低成本,包括限制外部招聘、员工重组以及其他行动。这些行动导致了公司整体员工人数的减少。(界面)

2小时前

谷歌继续上新:推理模型2.5 Pro发布,多项测试击败OpenAI和Grok

谷歌宣布推出“最智能的AI模型”Gemini 2.5系列,实验版Gemini 2.5 Pro是该系列上线的首款推理模型。据介绍,实验版Gemini 2.5 Pro是谷歌旗下最先进的复杂任务模型,展示了强大的推理和代码能力,并拥有Gemini系列此前各模型所具有的全部功能。目前,实验版Gemini 2.5 Pro在GPQA和AIME 2025等多项基准测试任务中取得了优异成绩,并以39分的显著优势在测试人类偏好的大模型竞技场Chatbot Arena榜上排名第一,超越了Grok-3和GPT-4.5。(财联社)

2小时前

中国人寿:2024年净利润1069.35亿元,同比增长108.9%

36氪获悉,中国人寿发布2024年年度报告,2024年营业收入5285.67亿元,同比增长30.5%;归属于母公司股东的净利润1069.35亿元,同比增长108.9%。公司拟向全体股东派发2024年末期现金股利每股人民币0.45元(含税)。

2小时前

本页详细列出关于位元堂的品牌信息,含品牌所属公司介绍,位元堂所处行业的品牌地位及优势。
咨询